Owing to limited responses in the Phase 1a study, the changes in circulating cell-death markers were not evaluable. Future studies with dulanermin are needed to determine the utility of these assays with respect to providing evidence of activity or predicting overall response.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2011) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: